Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 3/20 | 0.55 |
| ▸ | KLK5 | Q9Y337 | 2/20 | 0.55 |
| ▸ | CACNA1B | Q00975 | 5/20 | 0.52 |
| ▸ | PPARA | Q07869 | 2/20 | 0.47 |
| ▸ | TACR1 | P25103 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 3/20 | 0.45 |
| ▸ | SYK | P43405 | 1/20 | 0.45 |
| ▸ | CTSL | P07711 | 2/20 | 0.45 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | CTSK | P43235 | 2/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | AKT1 | P31749 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8059266 | 1.00 | KLK7 (0.55) | KLK7KLK5CACNA1BPPARATACR1 | |
| SCHEMBL29400686 | 0.92 | KLK7 (0.60) | KLK7KLK5CACNA1BPPARACTSS | |
| SCHEMBL29401031 | 0.90 | KLK7 (0.47) | KLK7KLK5CACNA1BPPARACTSS | |
| SCHEMBL2584726 | 0.88 | KLK7 (0.51) | KLK7KLK5CACNA1BPPARACTSS | |
| SCHEMBL17177676 | 0.88 | KLK7 (0.51) | KLK7KLK5CACNA1BPPARACTSS | |
| SCHEMBL18206895 | 0.85 | CACNA1B (0.41) | KLK7KLK5CACNA1BCTSSCTSL | |
| SCHEMBL18206897 | 0.85 | CACNA1B (0.41) | KLK7KLK5CACNA1BCTSSCTSL | |
| SCHEMBL4370045 | 0.85 | KLK5 (0.65) | KLK7KLK5CACNA1BPPARATACR1 | |
| SCHEMBL29401078 | 0.84 | KLK7 (0.49) | KLK7KLK5PPARACTSSSYK | |
| SCHEMBL29808549 | 0.84 | KLK7 (0.49) | KLK7KLK5PPARACTSSSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7557137-B2 | Gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-07-07 | — | — | US | disclosed |
| US-20070265331-A1 | Novel gamma-lactams as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-11-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265331-A1 | Novel gamma-lactams as beta-secretase inhibitors | BACE1, APP, BACE2 | KLK7 3979/4885KLK5 3423/4885CACNA1B 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.